HeartWare vote for US move

By Dylan Bushell-Embling
Wednesday, 17 September, 2008

Medical device company HeartWare [ASX: HTW] has received federal court approval to go ahead with shareholder meetings to vote on its plans to redomicile in the US.

Meetings are planned for October 22.

HeartWare has appointed BDO Kendalls Corporate Finance (QLD) to independently assess the proposed scheme. BDO has determined that the scheme is in the best interest of all stockholders.

Related News

Scientists uncover how cancer cells hide from immune system

By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...

Vanillin flavouring in vapes may disrupt embryo development

Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...

Heart valve tissues created from stem cells

The breakthrough should help advance our understanding into how human heart valves develop,...

Content from other channels on our network

Sale of Hobart Private Hospital to Calvary raises concerns

Opinion: The growing risk of AI-driven self-diagnosis in breast health

A new national approach to clinical governance

Opinion: The debate over the government's aged care algorithm is missing the point

Commonwealth Home Support Program extended to 30 June 2029

Engineers Australia supports national engineer registration

Asahi to use recycled material for all plastic soft drink bottles

Queensland Government and CSIRO launch free R&D program for SMEs

Applications open in WA for submarine sustainment contracts

Construction begins on WA gallium project

APPEX 2027: The Industry Event Powered by APPMA Returns to Melbourne

From bottleneck to backbone: rethinking water in F&B manufacturing

Barry Callebaut appoints new Chief Operating Officer

Arnott's Group celebrates its suppliers at Sydney event

Record growth for food and grocery manufacturing sector, AFGC reports

  • All content Copyright © 2026 Westwick-Farrow Pty Ltd